The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Cost per delivered dose, which is the number that matters

This is a generated summary. It shows the 9 most-liked posts from a topic of 60, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
AT
a.teixeiraTL2 Moderator Solution19 Aug 2025#3

Worth separating two things that the opening post runs together.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

23 likes 11mo
AK
a.kirchnerTL2 Moderator11 Sep 2025#7

List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially. List price is not what anyone pays.

31 likes 11mo
BN
bench_notesTL4 Moderator30 Sep 2025#11

This follows post #8 rather than contradicting it.

Compute cost per delivered dose at your dose if you want a number you can act on. That requires knowing your dose, vial volume, and whether you are using a vial or a pen.

27 likes 10mo
ES
e.steinerTL2 Moderator26 Nov 2025#25

Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be compared on price per milligram alone because dead volume, wastage, and number of doses actually obtainable differ.

29 likes 8mo
MP
mira.patelTL4 Admin29 Dec 2025#34
Staff post. Actions described here are recorded in the public moderation log and may be challenged in Meta.

Coming back to post #32, because the follow-up matters more than the original answer.

Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers and manufacturers.

30 likes 7mo
O
OstrowskiTL2Member15 Jan 2026#39

Biosimilars and future generics: as patents expire, biosimilar and generic versions might become available and prices might fall. That has already happened for some proteins; incretin agonist pricing might follow.

31 likes 6mo
PO
pe.onwukaTL2 Moderator7 Feb 2026#46

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

32 likes 6mo
SR
s.roosTL2 Moderator20 Feb 2026#50

Compute cost per delivered dose at your dose if you want a number you can act on. That requires knowing your dose, vial volume, and whether you are using a vial or a pen.

24 likes 5mo
NR
n.rowntreeTL3Regular11 Mar 2026#56

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

26 likes 5mo

Read the full topic (60 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this…
DADVDBRMMP+21 25 55k 13mo
Revisiting: List price versus negotiated price versus what you pay
Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
VKBVIABDGR+24 28 50k 12mo
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
MAOCASMIDB+4 8 658 14mo
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
LCGFVTPOO+78 83 33k 1mo
Cost per milligram, computed honestly across formats
Posting this under the heading it deserves: Cost per milligram, computed honestly across formats Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
BVTDV 2 47k 18mo

Related topics — sharing the tags cost per milligram, data table, compounding

TopicParticipantsRepliesViewsActivity
Gradient steepness and apparent purity: a worked comparison
On the subject in the title: Gradient steepness and apparent purity: a worked comparison Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in…
POLFTI 2 51k 22mo
Coming back to: A community side-effect dataset, with its response rate and biases
Posting this under the heading it deserves: A community side-effect dataset, with its response rate and biases Everything below is what sits behind that. Working through the identity arithmetic and I would…
JRNKNAPMFV+96 101 33k 2d
Designing a personal experiment that could change your mind
Posting this under the heading it deserves: Designing a personal experiment that could change your mind Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before…
MGECFACHG+2 6 695 6mo
[2026 update] Area percent versus weight percent: the confusion that causes most arguments
On the subject in the title: Area percent versus weight percent: the confusion that causes most arguments Working notes rather than a conclusion. Posting the method first, because I know what the first three…
BIISCJBSG+65 70 1.1k 16d
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
TPHFRMIBCR+37 42 32k 11d